Clinical Trial Update: Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tacrolimus and sirolimus as graft-versus-host disease prophylaxis after allogeneic non-myeloablative peripheral blood stem cell transpl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Prograf (Tacrolimus)
• Rapamune (sirolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Graft Versus Host Disease, GVHD | Phase 2 | Status: COMPLETED | Results posted: 2014-04-08